-

Shareholder Alert: Robbins LLP Reminds Investors Lyft, Inc. (LYFT) Sued for Misleading Shareholders

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that purchasers of Lyft, Inc. (NASDAQ: LYFT) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1933 pursuant to the company's March 2019 initial public offering ("IPO"). Lyft is a ridesharing company.

If you suffered a loss as a result of Lyft's misconduct, click here.

Lyft, Inc. (LYFT) Accused of Inflating its IPO Price

According to the complaint, Lyft held its IPO in March 2019, offering its stock at $72.00 per share for anticipated total proceeds of over $2 billion. In the immediate wake of the IPO, Lyft's stock price declined as investors raised concerns that Lyft's reported market share may have been overstated. Investor concerns were exacerbated on April 10, 2019, by reports that Uber, Lyft's much larger competitor, was preparing to file for an initial public offering. The next day, Uber’s Form S-1 claimed a market share of greater than 65%, which undermined Lyft’s market share claim of 39%. A few days later, the New York Times reported that Lyft’s bikeshare program, Citi Bike, was pulling 1,000 bicycles from multiple cities in the wake of dozens of reported injuries and safety concerns. Lyft’s stock has declined in response to these revelations, and now trades at around $54 per share—almost 25% below its IPO price.

Lyft, Inc. (LYFT) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:LYFT

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom